Building Stochastic Models for Cancer Growth and Treatment

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Unknown venue

• Publication date

  2010-12-08

• Fields of study

  Medicine, Mathematics

• Identifiers
  DOI 10.1201/B10407-16
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic Myeloid Leukemia

  2020cited by this paper
• Stem Cell Proliferation and Quiescence—Two Sides of the Same Coin

  2009cited by this paper
• Combination of Two but Not Three Current Targeted Drugs Can Improve Therapy of Chronic Myeloid Leukemia

  2009cited by this paper
• The fixed-size Luria-Delbruck model with a nonzero death rate.

  2007cited by this paper
• Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses

  2007cited by this paper
• Effect of Cellular Quiescence on the Success of Targeted CML Therapy

  2007cited by this paper
• Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer.

  2007cited by this paper
• Optimizing therapy of chronic myeloid leukemia.

  2007cited by this paper
• Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

  2007cited by this paper
• Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.

  2006cited by this paper
• Evolution of resistance to cancer therapy.

  2006cited by this paper
• Stochastic modeling of drug resistance in cancer.

  2006cited by this paper
• Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

  2006cited by this paper
• Drug resistance in cancer: principles of emergence and prevention.

  2005cited by this paper
• The mathematical modelling of adjuvant chemotherapy scheduling: Incorporating the effects of protocol rest phases and pharmacokinetics

  2005cited by this paper
• The biology of CML blast crisis.

  2004cited by this paper
• Strategies to overcome resistance to targeted protein kinase inhibitors

  2004cited by this paper
• Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease

  2004cited by this paper
• Imatinib as a paradigm of targeted therapies.

  2004cited by this paper
• The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling

  2004cited by this paper
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• Mechanisms and implications of imatinib resistance mutations in BCR-ABL

  2004cited by this paper
• New tools for cancer chemotherapy: computational assistance for tailoring treatments.

  2003cited by this paper
• Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors.

  2003cited by this paper
• Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib

  2003cited by this paper
• Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

  2003cited by this paper
• Overcoming resistance to imatinib by combining targeted agents.

  2003cited by this paper
• Chronic myelogenous leukemia: mechanisms underlying disease progression

  2002cited by this paper
• Resistance in the land of molecular cancer therapeutics.

  2002cited by this paper
• Recent advancements in the treatment of chronic myelogenous leukemia.

  2002cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy.

  2000cited by this paper
• Signatures of population expansion in microsatellite repeat data.

  1998cited by this paper
• Growth of nonnecrotic tumors in the presence and absence of inhibitors.

  1995cited by this paper
• Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis.

  1994cited by this paper
• Time-continuous branching walk models of unstable gene amplification.

  1994cited by this paper
• Gene amplification by unequal sister chromatid exchange: probabilistic modeling and analysis of drug resistance data.

  1994cited by this paper
• Use of mathematical models for understanding the dynamics of gene amplification.

  1993cited by this paper
• A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs.

  1992cited by this paper
• The dynamics of gene amplification described as a multitype compartmental model and as a branching process.

  1991cited by this paper
• Mathematical models of gene amplification with applications to cellular drug resistance and tumorigenicity.

  1990cited by this paper
• Pitfalls and practice of Luria-Delbrück fluctuation analysis: a review.

  1988cited by this paper
• Genetic instability in the development of drug resistance.

  1985cited by this paper
• A model for tumor response to chemotherapy: an integration of the stem cell and somatic mutation hypotheses.

  1985cited by this paper

• Controlling and stabilizing unpredictable behavior of metabolic reactions and carcinogenesis in biological systems

  2019cites this paper
• Controlling and stabilizing unpredictable behavior of metabolic reactions and carcinogenesis in biological systems

  2019cites this paper
• In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model

  2016cites this paper
• Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data

  2016cites this paper